DRUG logo

DRUG Bright Minds Biosciences Inc.

NASDAQ · Biotechnology · Healthcare

$20.76
+0.25 (+1.22%)

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials …

Market Cap: $204.78Mwww.brightmindsbio.com

Price

No data yet.

Social Signal Score

22
5d
5
1 mentions
—
30d
30
5 mentions
—
60d
27
6 mentions
—
90d
26
9 mentions
—
news: 9

Analyst Ratings

5 analysts
Buyconsensus
Strong Buy 0Buy 5Hold 0Sell 0Strong Sell 0
Avg price target$138+564.7%
Low $37Median $147.5High $220
Current Consensus

Revenue

$0.00
$0.00
Dec 2019Jun 2026

Analyst Estimates

FY2025
$-2.04
$-2.51–$-1.59
4 analysts
FY2026
$-3.87
$-4.25–$-3.20
6 analysts
FY2027
$-8.72
$-12.52–$-6.14
6 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Ian McDonald
Sector
Healthcare
Industry
Biotechnology
Employees
26
Beta
0.09
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
69.70
www.brightmindsbio.com